Chinyere Kemet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chinyere Kemet has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Hui Feng
Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA
3 shared publications - Xiaodan Qin
Departments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118, USA
2 shared publications - Alexander E. Floru
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA
1 shared publication - Andrew Lam
Departments of Pharmacology, Physiology & Biophysics and Medicine, Section of Hematology and Medical Oncology, Cancer Research Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
1 shared publication - Catherine J. Wu
Dana-Farber Cancer Institute
1 shared publication - Ching-Ti Liu
Boston University School of Public Health
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (10)
Janitors at Work: The Multifaceted Role of the P97-UFD1-NPL4 Complex
The regulatory pathways governing protein homeostasis are a delicate balance of protein synthesis and degradation. At the core of proteolysis is a molecular “cleaning crew” composed of the P97 ATPase, ubiquitin fusion degradation 1 (UFD1), and nuclear protein localization 4 (NPL4). The ATPase activity of P97 drives the formation and activity of this complex, which is also regulated by post-translational modifications and ubiquitin regulatory X-domain proteins. Notably, the P97-UFD1-NPL4 complex plays a critical role in endoplasmic reticulum-associated degradation (ERAD), by retrotranslocating misfolded proteins from the endoplasmic reticulum (ER) to the cytosol. Beyond ERAD, this complex also targets proteins from mitochondria, ribosomes, and chromatin to regulate cellular processes such as organelle homeostasis, cell cycle progression, DNA replication, and DNA repair. The aberrant activity of the P97-UFD1-NPL4 complex can either accelerate or impair the removal of misfolded, unfolded, and regulatory proteins, disrupting cellular homeostasis and inducing various disorders. Significant efforts have been made to develop therapeutics that inhibit complex functions. However, to identify a suitable strategy, it is crucial to understand the molecular mechanisms linking the function of the complex to disease progression. In this review, we summarize the multifaceted roles of the P97-UFD1-NPL4 complex in protein quality control, discuss how its dysfunction leads to disease, and explore ongoing strategies to target the complex.
- 15 October 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (10)
Open AccessJanitors at Work: The Multifaceted Role of the P97-UFD1-NPL4 Complex
The regulatory pathways governing protein homeostasis are a delicate balance of protein synthesis and degradation. At the core of proteolysis is a molecular “cleaning crew” composed of the P97 ATPase, ubiquitin fusion degradation 1 (UFD1), and nuclear protein localization 4 (NPL4). The ATPase activity of P97 drives the formation and activity of this complex, which is also regulated by post-translational modifications and ubiquitin regulatory X-domain proteins. Notably, the P97-UFD1-NPL4 complex plays a critical role in endoplasmic reticulum-associated degradation (ERAD), by retrotranslocating misfolded proteins from the endoplasmic reticulum (ER) to the cytosol. Beyond ERAD, this complex also targets proteins from mitochondria, ribosomes, and chromatin to regulate cellular processes such as organelle homeostasis, cell cycle progression, DNA replication, and DNA repair. The aberrant activity of the P97-UFD1-NPL4 complex can either accelerate or impair the removal of misfolded, unfolded, and regulatory proteins, disrupting cellular homeostasis and inducing various disorders. Significant efforts have been made to develop therapeutics that inhibit complex functions. However, to identify a suitable strategy, it is crucial to understand the molecular mechanisms linking the function of the complex to disease progression. In this review, we summarize the multifaceted roles of the P97-UFD1-NPL4 complex in protein quality control, discuss how its dysfunction leads to disease, and explore ongoing strategies to target the complex.
- Open Access
- 15 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (11) , eadh9547
CKLF instigates a “cold” microenvironment to promote MYCN-mediated tumor aggressiveness
Solid tumors, especially those with aberrant MYCN activation, often harbor an immunosuppressive microenvironment to fuel malignant growth and trigger treatment resistance. Despite this knowledge, there are no effective strategies to tackle this problem. We found that chemokine-like factor ( CKLF ) is highly expressed by various solid tumor cells and transcriptionally up-regulated by MYCN. Using the MYCN-driven high-risk neuroblastoma as a model system, we demonstrated that as early as the premalignant stage, tumor cells secrete CKLF to attract CCR4-expressing CD4 + cells, inducing immunosuppression and tumor aggression. Genetic depletion of CD4 + T regulatory cells abolishes the immunorestrictive and protumorigenic effects of CKLF. Our work supports that disrupting CKLF-mediated cross-talk between tumor and CD4 + suppressor cells represents a promising immunotherapeutic approach to battling MYCN-driven tumors.
- 15 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (11) , eadh9547
Open AccessCKLF instigates a “cold” microenvironment to promote MYCN-mediated tumor aggressiveness
Solid tumors, especially those with aberrant MYCN activation, often harbor an immunosuppressive microenvironment to fuel malignant growth and trigger treatment resistance. Despite this knowledge, there are no effective strategies to tackle this problem. We found that chemokine-like factor ( CKLF ) is highly expressed by various solid tumor cells and transcriptionally up-regulated by MYCN. Using the MYCN-driven high-risk neuroblastoma as a model system, we demonstrated that as early as the premalignant stage, tumor cells secrete CKLF to attract CCR4-expressing CD4 + cells, inducing immunosuppression and tumor aggression. Genetic depletion of CD4 + T regulatory cells abolishes the immunorestrictive and protumorigenic effects of CKLF. Our work supports that disrupting CKLF-mediated cross-talk between tumor and CD4 + suppressor cells represents a promising immunotherapeutic approach to battling MYCN-driven tumors.
- Open Access
- 8 February 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Fishing for drugs
Screening for drugs that disrupt embryonic development in zebrafish can help identify treatments that suppress metastasis.
- 8 February 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessFishing for drugs
Screening for drugs that disrupt embryonic development in zebrafish can help identify treatments that suppress metastasis.